NASDAQ:TCRX TScan Therapeutics (TCRX) Stock Price, News & Analysis $1.27 +0.07 (+5.37%) As of 12:14 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About TScan Therapeutics Stock (NASDAQ:TCRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TScan Therapeutics alerts:Sign Up Key Stats Today's Range$1.23▼$1.3450-Day Range$0.94▼$1.4352-Week Range$0.88▼$2.57Volume715,468 shsAverage Volume738,708 shsMarket Capitalization$72.55 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins. The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors. TScan has established strategic collaborations with major pharmaceutical partners to advance its lead candidates through clinical development. These partnerships enable the company to combine its TCR discovery capabilities with the resources and expertise of established drug developers, while retaining the ability to progress additional assets independently. Founded in 2018 and headquartered in Cambridge, Massachusetts, TScan Therapeutics went public in late 2021. Under the leadership of Chief Executive Officer Kenneth Song, the company employs a multidisciplinary team of immunologists, molecular biologists and data scientists. While its core operations are based in the United States, TScan’s research partnerships and clinical trial activities extend globally, reflecting its ambition to deliver novel T-cell therapies to patients around the world.AI Generated. May Contain Errors. Read More TScan Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreTCRX MarketRank™: TScan Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 456th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingTScan Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialTScan Therapeutics has a consensus price target of $6.00, representing about 374.3% upside from its current price of $1.27.Amount of Analyst CoverageTScan Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about TScan Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TScan Therapeutics are expected to grow in the coming year, from ($1.02) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TScan Therapeutics is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TScan Therapeutics is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTScan Therapeutics has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for TCRX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTScan Therapeutics does not currently pay a dividend.Dividend GrowthTScan Therapeutics does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment0.19 News SentimentTScan Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for TScan Therapeutics this week, compared to 2 articles on an average week.Search Interest12 people have searched for TCRX on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.MarketBeat Follows5 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TScan Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.25% of the stock of TScan Therapeutics is held by insiders.Percentage Held by Institutions82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TScan Therapeutics' insider trading history. Receive TCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TCRX Stock News HeadlinesTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6 at 7:00 AM | globenewswire.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Given Consensus Rating of "Hold" by AnalystsMay 5 at 2:40 AM | americanbankingnews.comLouis Navellier: “I'm dropping everything on May 13.” Here's why.47-year Wall Street veteran Louis Navellier says a rare market pattern is forming for only the fifth time in his career - each previous instance was triggered by a Federal Reserve shift and preceded gains of 1,100% to 2,900% in select small-cap stocks. On May 13 at 1 p.m. ET, Navellier is hosting the 10X Fed Shock Summit to walk through what he sees unfolding before the new Fed Chair takes over on May 15. Sign up and receive his 53-stock 'Exclusion List' free, plus his single highest-conviction pick named live.May 8 at 1:00 AM | Stansberry Research (Ad)TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual MeetingApril 27, 2026 | globenewswire.comTScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | globenewswire.comTScan Therapeutics Consolidates Finance Leadership After Officer ResignationApril 2, 2026 | tipranks.comTScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 4, 2026 | globenewswire.comTScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102 ...February 26, 2026 | markets.businessinsider.comSee More Headlines TCRX Stock Analysis - Frequently Asked Questions How have TCRX shares performed this year? TScan Therapeutics' stock was trading at $1.00 at the beginning of 2026. Since then, TCRX shares have increased by 27.5% and is now trading at $1.2750. How were TScan Therapeutics' earnings last quarter? TScan Therapeutics, Inc. (NASDAQ:TCRX) released its earnings results on Wednesday, May, 6th. The company reported ($0.22) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.22). The firm had revenue of $0.98 million for the quarter, compared to analysts' expectations of $2.50 million. TScan Therapeutics had a negative trailing twelve-month return on equity of 84.02% and a negative net margin of 1,360.61%. When did TScan Therapeutics IPO? TScan Therapeutics (TCRX) raised $107 million in an initial public offering on Thursday, July 15th 2021. The company issued 6,666,667 shares at $15.00-$17.00 per share. Who are TScan Therapeutics' major shareholders? Top institutional investors of TScan Therapeutics include Dimensional Fund Advisors LP (0.11%) and Kestra Advisory Services LLC (0.11%). Insiders that own company stock include Lynx1 Capital Management Lp, Timothy J Barberich, Barbara Klencke and Zoran Zdraveski. View institutional ownership trends. How do I buy shares of TScan Therapeutics? Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TScan Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TScan Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings5/06/2026Today5/08/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TCRX CIK1783328 Webwww.tscan.com Phone857-399-9500FaxN/AEmployees100Year Founded2018Price Target and Rating Average Price Target for TScan Therapeutics$6.00 High Price Target$7.00 Low Price Target$5.00 Potential Upside/Downside+374.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$129.77 million Net Margins-1,360.61% Pretax Margin-1,256.81% Return on Equity-84.02% Return on Assets-47.23% Debt Debt-to-Equity Ratio0.26 Current Ratio8.41 Quick Ratio8.41 Sales & Book Value Annual Sales$10.32 million Price / Sales6.97 Cash FlowN/A Price / Cash FlowN/A Book Value$2.16 per share Price / Book0.59Miscellaneous Outstanding Shares56,900,000Free Float53,346,000Market Cap$71.98 million OptionableNot Optionable Beta1.06 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:TCRX) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | Sponsored‘Please’: OpenAI CEO Sam Altman Begs Small Company for HelpSpaceX 'Dark Energy' Replaces Foreign Oil For years, we've been told SpaceX is a rocket company. But accord...Altimetry | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TCRX Stock Alerts